colorectal cancer

June 2008
Annals of Oncology;Jun2008 Supplement 5, Vol. 19, pv141
Academic Journal
The article presents abstracts on colorectal cancer which include incidence and clinical implications of venous thromboembolism in advanced colorectal cancer, restaging after preoperative chemoradiation for rectal cancer, and molecular predictors of cetuximab resistance in colorectal cancer patients.


Related Articles

  • War on Cancer. Moss, Ralph // Townsend Letter;Jan2014, Issue 366, p34 

    The article reports updates on the state of progress in treating metastatic stage IV colorectal cancer (mCRC) with chemotherapeutic agents as of December 2013. According to the article, the U.S. Food and Drug Administration (FDA) has approved several targeted therapies for mCRC including...

  • Perioperative FOLFOX4 plus bevacizumab for initially unresectable advanced colorectal cancer (NAVIGATE-CRC-01). Mitsukuni Suenaga; Yoshiya Fujimoto; Satoshi Matsusaka; Eiji Shinozaki; Takashi Akiyoshi; Satoshi Nagayama; Yosuke Fukunaga; Masatoshi Oya; Masashi Ueno; Nobuyuki Mizunuma; Toshiharu Yamaguchi // OncoTargets & Therapy;2015, Vol. 8, p1111 

    Background: Perioperative chemotherapy combined with surgery for liver metastases is considered an active strategy in metastatic colorectal cancer (CRC). However, its impact on initially unresectable, previously untreated advanced CRC, regardless of concurrent metastases, remains to be...

  • Current controversies in the management of metastatic colorectal cancer. Vera, Ruth; Alonso, Vicente; Gállego, Javier; González, Encarnación; Guillén-Ponce, Carmen; Pericay, Carles; Rivera, Fernando; Safont, Mª; Valladares-Ayerbes, Manuel; Gállego, Javier; González, Encarnación; Guillén-Ponce, Carmen; Safont, M José // Cancer Chemotherapy & Pharmacology;Oct2015, Vol. 76 Issue 4, p659 

    The factors affecting the decisions for the treatment for patients with metastatic colorectal cancer (mCRC) are related to the patient, the tumor, and the treatment itself. Both cetuximab and panitumumab are anti-EGFR monoclonal antibody options for patients with RAS wild-type tumors. Several...

  • Cetuximab.  // Reactions Weekly;7/14/2007, Issue 1160, p13 

    The article describes cases of two men with metastatic colorectal cancer who developed severe infusion reactions immediately after starting their first cetuximab infusion. The first patient, a 62-year-old man, experienced a warm sensation that spread from his back to his whole body after taking...

  • Adding cetuximab to capecitabine plus oxaliplatin (XELOX) in first-line treatment of metastatic colorectal cancer: a randomized phase II trial of the Swiss Group for Clinical Cancer Research SAKK. M. Borner; D. Koeberle; R. Von Moos; P. Saletti; D. Rauch; V. Hess; A. Trojan; D. Helbling; B. Pestalozzi; C. Caspar; T. Ruhstaller; A. Roth; A. Kappeler; D. Dietrich; D. Lanz; W. Mingrone; Bern; Switzerland; for the Swiss Group for Clinical Cancer Research (SAKK) // Annals of Oncology;Jul2008, Vol. 19 Issue 7, p1288 

    Background: To determine the activity and tolerability of adding cetuximab to the oxaliplatin and capecitabine (XELOX) combination in first-line treatment of metastatic colorectal cancer (MCC). Patients and methods: In a multicenter two-arm phase II trial, patients were randomized to receive...

  • FCGR polymorphisms and cetuximab efficacy in chemorefractory metastatic colorectal cancer: an international consortium study. Geva, Ravit; Vecchione, Loredana; Kalogeras, Konstantinos T.; Jensen, Benny Vittrup; Lenz, Heinz-Josef; Takayuki Yoshino; Paez, David; Montagut, Clara; Souglakos, John; Cappuzzo, Federico; Cervantes, Andrés; Frattini, Milo; Fountzilas, George; Johansen, Julia S.; Høgdall, Estrid Vilma; Wu Zhang; Dongyun Yang; Kentaro Yamazaki; Tomohiro Nishina; Papamichael, Demetris // Gut;Jun2015, Vol. 64 Issue 6, p921 

    Objective: We aimed to better clarify the role of germline variants of the FCG2 receptor, FCGR2A-H131R and FCGR3A-V158F, on the therapeutic efficacy of cetuximab in metastatic colorectal cancer (mCRC). A large cohort with sufficient statistical power was assembled. Design: To show a HR advantage...

  • Mologen's dSLIM immmunomodulators evaluated in clinical phase II study against colorectal carcinoma.  // PharmaWatch: Cancer;August 2003, Vol. 2 Issue 8, p11 

    Reports that German biotechnology firm Mologen has successfully completed a clinical phase II study that was aimed at analyzing the safety and efficacy of experimental anti-colorectal carcinoma drug dSLIM. Immune responses elicited by the experimental substance, depending on their structure.

  • Quality indicators for colorectal cancer surgery and care according to patient-, tumor-, and hospital-related factors. Mathoulin-P‚lissier, Simone; B‚couarn, Yves; Belleann‚e, GeneviŠve; Pinon, Elodie; Jaffr‚, Anne; Coureau, Ga‰lle; Auby, Dominique; Renaud-Salis, Jean-Louis; Rullier, Eric // BMC Cancer;2012, Vol. 12 Issue 1, p297 

    Background: Colorectal cancer (CRC) care has improved considerably, particularly since the implementation of a quality of care program centered on national evidence-based guidelines. Formal quality assessment is however still needed. The aim of this research was to identify factors associated...

  • Tumor Diameter Is an Easy and Useful Predictor of Recurrence in Stage II Colorectal Cancer. Maeda, Chiyo; Hidaka, Eiji; Mori, Yuichi; Mukai, Shumpei; Miyachi, Hideyuki; Sawada, Naruhiko; Ishida, Fumio; Kudo, Shin-ei // Digestive Surgery;Sep2015, Vol. 32 Issue 5, p338 

    Background/Aims: Adjuvant chemotherapy for stage II colorectal cancer (CRC) can generally be administered to high-risk subgroups. To better identify these patients, we aimed at assessing factors that affect recurrence. Methods: In our hospital, 432 colon and 96 rectal stage II cancer patients...


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics